Usage: Adakveo reduces the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Usage: Afinitor treats postmenopausal women with advanced HR-positive, HER2-negative breast cancer; adults with progressive neuroendocrine tumors or advanced renal cell carcinoma; and tuberous sclerosis complex-related renal angiomyolipoma, SEGA, and partial-onset seizures (ages 2+).